397 results about "Polyarthritis Rheumatica" patented technology

The invention discloses a novel benzofuran component in eupatorium chinense and application of the benzofuran component in anti-inflammatory activity. The obtained compound is separated from an eupatorium chinense extract. The eupatorium chinense root extract is separated by using an extraction method, macroporous adsorption resin impurity removal, Sephadex LH-20 gel column chromatography, high performance liquid chromatography and other methods. According to the present invention, all the separated compounds and the analogues thereof have good inhibition activity on target cyclooxygenase-2 of inflammation-related diseases, and have good inhibition activity on COX-2 enzyme, and the molecular docking experiment results show that the compounds and the target proteins have good binding energy. Therefore, the compound can be used for preparing drugs for treating inflammatory related diseases, or anti-inflammatory and analgesic drugs, or tumor drugs by inhibiting COX-2 enzyme, such as drugs for rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, Alzheimer's disease and the like, and related natural lead compounds are provided.

The invention belongs to the field of biological medicines, and particularly relates to application of loganic acid in preparation of a medicine for treating arthritis. Specifically, through experimental research of a collagen-induced arthritis mouse model, the loganin acid is found to be capable of remarkably relieving arthritis symptoms, relieving joint swelling, synovitis and cartilage injury in a dose-dependent manner, and reducing the levels of proinflammatory factors TNF-alpha and IL-6 in plasma. By further combining 16S rRNA sequencing analysis, the loganic acid can remarkably regulate the intestinal microbiota structure of arthritis mice, increase the abundance of Lactobacillus murinus in the intestinal tract and promote the generation of tryptophan metabolite indole-3-acetic acid, so that the effect of resisting rheumatoid arthritis is achieved through an intestinal flora dependent mechanism. Therefore, the invention provides a new application of loganin acid in preparation of a medicine for treating arthritis, and the compound has further research and application values as a potential small molecule medicine.

The present disclosure provides methods of treating rheumatoid arthritis comprising administering a MNK inhibitor.

The invention discloses Witzia ciliaris NCU-33 and application thereof, and belongs to the technical field of microbial medicines. The bacillus coagulans NCU-33 is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number of the bacillus coagulans NCU-33 is CGMCC NO.31779. The strain is separated from a fresh excrement sample of healthy people; the strain is capable of ameliorating and / or preventing rheumatoid arthritis by anti-inflammatory and immunomodulatory effects.

The invention provides a nitric oxide fluorescent probe with aggregation-induced emission characteristics and a preparation method and application thereof. The structural formula of the nitric oxide fluorescent probe is shown in the specification. The nitric oxide fluorescent probe provided by the invention is high in detection sensitivity, high in response speed, excellent in NO selectivity and AIE characteristic, wide in application range, not only suitable for liquid-phase and gas-phase NO detection, but also capable of realizing high-efficiency real-time detection of NO in body fluid, cells and living body samples, and wide in application prospect. The method can be used for diagnosis of diseases such as inflammation (rheumatoid arthritis), tumor microenvironment and the like, high-throughput drug screening and environment monitoring.

A method for determining if an agent is suitable for treating a Rheumatoid Arthritis (RA) patient, the method comprising determining the profile of a first, second and / or third marker panel in a sample from the patient, wherein the agent is selected from an agent that downregulates TNF mediated signalling, an agent that downregulates IL-6 mediated signalling and a B cell targeted therapy.

The application discloses a use of total iridoid glycosides in radix morindae officinalis in preparation of a medicine for reducing side effects of methotrexate, and the total iridoid glycosides in radix morindae officinalis are effective traditional Chinese medicine components prepared by extraction and separation from radix morindae officinalis medicinal materials. The total iridoid glycosides in radix morindae officinalis and main component crystal larkspur glycoside are combined with methotrexate to treat rheumatoid arthritis rats, and the animal experiment proves that the combined administration can effectively treat inflammation of the rheumatoid arthritis rats, and can inhibit bone loss, especially can effectively reduce side effects caused by methotrexate, reduce damage caused by methotrexate to the organism, make the application more safe and effective, and provide a new treatment strategy for rheumatoid arthritis.

The present invention relates to the use of an ROR inverse agonist or a pharmaceutically acceptable salt thereof for the preparation of a medicament for modulating ROR in a patient and / or for controlling autoimmune diseases and antibody-mediated rejection in a patient. The ROR-mediated diseases or autoimmune diseases include HIV, cancer, celiac disease, type 1 diabetes, Graves' disease (Graves' disease), inflammatory bowel disease, multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, asthma, dermatitis, fatty liver disease, Crohn's disease (Crohn's disease), cardiovascular disease, inflammatory disease, nervous system disorders, multiple sclerosis, and the like. Acute respiratory distress syndrome and arteriosclerosis.

Provided is a bispecific antibody and use thereof, the bispecific antibody comprising: a first domain that specifically binds the interleukin-6 receptor IL-6R, and a second domain that specifically binds interleukin-23. The bispecific antibody can simultaneously target IL-6R and IL-23p19, with stronger specificity, more accurately targeting tumor cells and reducing the adverse effects of off-target toxicity and can perform a unique function to play a biological function that is difficult to achieve with monoclonal antibody drugs. Compared with monoclonal antibody combination therapies, it can also effectively reduce the cost of treatment and break the current upper limit of therapeutic efficacy in the treatment of autoimmune diseases such as rheumatoid arthritis and IBD.

The application relates to fused pyrimidinone derivatives of the general formula (I) which act as agonists of Triggering Receptor Expressed on Myeloid cells 2 (TREM2) useful for the treatment of Parkinson's disease, rheumatoid arthritis, Alzheimer's disease, amyotrophic lateral sclerosis, Nasu-Hakola disease, frontotemporal dementia, multiple sclerosis, prion disease, and stroke.

The present invention relates to a composition comprising 4-hexylresorcinol (4-HR) as an active ingredient for prevention or treatment of a bone disease, and a formulation thereof. The composition comprising 4-hexylresorcinol (4-HR) as an active ingredient, or an ointment thereof was found to improve bone thickness, density, and strength and control bone remodeling by promoting the differentiation of osteoblasts and suppressing the proliferation and differentiation of osteoclasts in osteoporosis-induced animal models. Thus, the composition or ointment comprising 4-hexylresorcinol (4-HR) as an active ingredient can be provided as a therapeutic agent for bone diseases including bone fracture, osteoarthritis, rheumatoid arthritis, and osteoporosis.

The invention provides a preparation method and application of graphene pain-relieving health-care paste, and the method comprises the following steps: mixing carrageenan with water to obtain a carrageenan solution, and carrying out ionization degradation on the carrageenan solution to obtain a carrageenan oligosaccharide solution; the preparation method comprises the following steps: stirring graphene oxide and a carrageenan oligosaccharide solution, cleaning to obtain a mixed solution, adding sodium alginate into the mixed solution to prepare a gel precursor, and adding an anhydrous calcium chloride solution and effective components into the gel precursor to obtain the pain-relieving gel, and drying the gel to obtain the health-care paste. The health-care ointment has the effects of promoting blood circulation, activating collaterals and inhibiting inflammation, and is suitable for various chronic pains such as rheumatic arthritis and lumbar muscle degeneration and acute pains such as traumatic injury and muscle strain; the composition is also suitable for auxiliary relieving of postoperative pain, and has safety and long-term effect. Due to the thermal conductivity of the graphene oxide in the health-care cream, local skin blood circulation can be accelerated, the permeation efficiency of the herbal extract is improved, and the medicine effect of the effective components is improved.

The invention discloses a traditional Chinese medicine liniment for treating rheumatoid arthritis and a preparation process thereof, the traditional Chinese medicine liniment is composed of a wind-dispelling and pain-relieving liquid medicine and auxiliary materials, the wind-dispelling and pain-relieving liquid medicine contains eight traditional Chinese medicines of thorny elaeagnus root, erythrina bark, kadsura longepedunculata root, waxberry root, ardisia crenata, rose mallow root, glabrous sarcandra herb and wikstroemia canescens root, and is prepared by ultrasonic extraction; the auxiliary materials comprise polyvinyl alcohol, a chitosan-acetic acid solution, glycerol, azone, methylparaben, vanillyl butyl ether and ethanol. The liniment is short in film forming time and good in stability, has excellent transdermal absorption performance and antioxidant activity, can remarkably relieve joint swelling of RA model mice, improve the pain threshold value, improve joint pathological injuries, achieve local precise long-acting administration, reduce side effects of the whole body and improve patient compliance, is suitable for clinical treatment of RA, and has a wide application prospect. The problems that an existing rheumatoid arthritis treatment medicine is large in side effect, and a traditional Chinese medicine preparation is short in efficacy duration and inconvenient to use are solved.

The invention discloses a traditional Chinese medicine composition for treating arthralgia, a traditional Chinese medicine preparation and a preparation method thereof, and belongs to the technical field of traditional Chinese medicine, and the traditional Chinese medicine composition comprises the following raw materials in parts by weight: 10-20 parts of vine of multiflower knotweed, 5-14 parts of rhizoma anemarrhenae, 10-20 parts of dandelion and 10-20 parts of bunge corydalis herb. The composition has a good treatment effect on rheumatoid arthritis, arthritis, arthralgia, muscular pain and the like caused by damp-heat, and can effectively solve the problem of limitation of existing medicines.

This invention belongs to the field of pharmaceutical technology, specifically relating to the application of oleanolic acid in promoting chondrogenic differentiation of chondrocytes. This invention discovers that oleanolic acid promotes the expression of proteoglycans and calcium deposition in ATDC5 cells undergoing chondrogenic differentiation, and also promotes the expression of ATDC5 cell chondrogenic differentiation markers. Therefore, it has the potential to be formulated into a drug that can promote chondrogenic differentiation of chondrocytes, thereby promoting cartilage repair and regeneration for the treatment of osteoarthritis and rheumatoid arthritis.

The present disclosure relates to compounds of Formula I and pharmaceutically acceptable salts thereof, wherein X, R1-R4, n and m have the meanings given in the specification. The compounds of formula I exhibit GPR183 antagonistic activity and are therefore useful in the treatment or prevention of disorders, conditions or diseases to which GRP183 antagonists are applicable, such as chronic pain, such as osteoarthritis, chronic lumbago, neuropathic pain, and immune system diseases, such as inflammatory bowel diseases, such as colitis and Crohn's disease, multiple sclerosis, rheumatoid arthritis, inflammatory lung diseases, and the like. , such as asthma and psoriasis.

The present invention relates to a composition and method for treating rheumatoid arthritis, comprising interleukins (ILs), including IL-1β, stimulated human umbilical cord mesenchymal stem cells (hUCMSCs). The IL stimulated hUCMSCs of the present invention may induce the apoptosis of fibroblast-like synoviocytes rheumatoid arthritis (HFLS-RA) cells. IL stimulated hUCMSCs are useful to alleviate RA symptoms, such as inflammation, swelling and cartilage erosion, and exhibit therapeutic effects on rheumatoid arthritis.

The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and / or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and / or prophylaxis of diseases, especially for treatment and / or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis.

The invention belongs to the technical field of medicines, and particularly relates to a triptolide nano-skeleton and a preparation method and application thereof, and the triptolide nano-skeleton comprises the following components by mass: 11%-20% of triptolide, 20%-60% of polyacrylic resin, and 20%-60% of mesoporous silica. The triptolide nano-skeleton provided by the invention is mainly composed of a drug triptolide, a high-molecular polymer material polyacrylic resin and a carrier material mesoporous silica, and a mixture formed by triptolide and polyacrylic resin is uniformly loaded on the mesoporous silica to form a solid preparation suitable for oral administration. The dissolution rate and oral absorption of the triptolide are remarkably increased, the treatment safety is ensured, meanwhile, the curative effect of the triptolide on rheumatoid arthritis is effectively enhanced, and the triptolide tablet has a good application prospect.

This invention relates to a novel use of IL-1β-ligand / IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1b ligand-IL-1 receptor interaction, IL-1b antibodies or IL-1 receptor antibodies, e.g. IL-1b binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1b binding compounds or IL-1 receptor binding compounds, and / or RNA compounds decreasing either IL-1b ligands or IL-1 receptor protein levels, in the treatment and / or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and / or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.

Disclosed herein is a method for treating, preventing, and / or slowing the progression of various chronic inflammatory condition groups including: (1) the Type 2 Diabetes group (Metabolic Syndrome (MET), obesity, hyperglycemia); (2) ARDS (Acute Respiratory Distress Syndrome); (3) chronic autoimmune inflammatory conditions (Rheumatoid Arthritis (RA), Lupus, and Psoriasis); (4) inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis; (5) metabolite group-mediated diseases (atherosclerosis, hypertension, and congestive heart failure); and (6) eating disorders, such as Prader-Willi Syndrome and other monogenic and symptomatic obesity disorders including leptin pathway defects, each method comprising orally administering a pharmaceutical composition comprising a denatonium salt. The present disclosure is based on the results of a series of studies that tracked biomarker cluster levels to track mediators of inflammatory conditions and mediators of gut signaling hormones in response to orally administered denatonium salts.

The present disclosure relates to the use of an anti-IL6 receptor antibody for treating rheumatoid arthritis in subjects with serum concentrations of certain biomarkers.

Provided herein is a methods for monitoring inflammatory disease activity in a subject comprising: (i) obtaining a sample from the subject; and (ii) measuring an autoantibody concentration in the sample using an immunoassay. Optionally, the inflammatory disease is rheumatoid arthritis (RA). Optionally, the autoantibody is an anti-citrullinated vimentin autoantibody (anti-Sa) or an anti-carbamylated protein autoantibody (anti-CarP). Optionally, the autoantibody concentration is correlated to a multi-disease biomarker activity (MBDA) score. Also provided herein are systems and kits for performing the method described herein.

This disclosure relates to methods for treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosus by using fenebrutinib, a Bruton's tyrosine kinase inhibitor, or a pharmaceutically acceptable salt thereof.

The invention discloses a construction method and application of a rheumatoid arthritis condition prediction model. The construction method comprises the following steps: acquiring a cross-modal data set; and training a multi-feature fusion network model based on the cross-modal data set. When the system is used, the cross-modal data set is formed by acquiring clinical big data, muscle-bone ultrasound, joint images and the like of historical patients suffering from rheumatoid arthritis, the multi-feature fusion network model is constructed based on the cross-modal data set, and the multi-feature fusion network model is convenient to deploy and use; according to the invention, primary condition prediction can be given according to the physical condition of each user, so that primary doctors can be helped to quickly screen out patients possibly suffering from rheumatoid arthritis, and the prediction result is relatively accurate.

Disclosed is a selenium-containing polyamino acid having a structure represented by formula (I) or a pharmaceutically acceptable salt thereof, wherein A, B, D, E, m, n, and x are as defined in the description. Also disclosed is a pharmaceutical composition containing the selenium-containing polyamino acid or a pharmaceutically acceptable salt thereof. Also disclosed is a use of the selenium-containing polyamino acid or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition containing the selenium-containing polyamino acid or the pharmaceutically acceptable salt thereof in the preparation of a drug for treating diseases selected from osteoarthritis, rheumatoid arthritis, and periodontitis. E[-(B)m-(A)n-D]x Formula (I)

Provided is a skeleton protection method, which comprises administering to a subject in need thereof an effective amount of a peptide comprising the amino acid sequence of SEQ ID NO: 1. The present invention proves that administering the peptide of SEQ ID NO: 1 can ameliorate cortical bone erosion of calcaneus bone resulting from rheumatoid arthritis (RA) and restore the decline of RA-induced bone mineral density. Therefore, the peptide of SEQ ID NO: 1 possesses a therapeutic effect for skeleton protection.

The invention discloses a compound for regulating the activity of micro RNA-124, the compound has a structure as shown in a formula (I), and the compound can be used for preventing or treating inflammatory diseases. Comprising but not limited to inflammatory bowel disease, rheumatoid arthritis, Crohn's disease, ulcerative colitis, multiple sclerosis, Alzheimer's disease, Paragins disease, osteoarthritis, atherosclerosis, ankylosing spondylitis, psoriasis, dermatitis, Sjogren syndrome, bronchitis, asthma and inflammation associated with colon cancer; the compounds are useful for treating colon cancer, and in particular inflammatory bowel disease, rheumatoid arthritis, Crohn's disease, ulcerative colitis, multiple sclerosis, osteoarthritis, ankylosing spondylitis, psoriasis, Sjogren syndrome, bronchitis, and inflammation associated with colon cancer.